For adult rheumatoid arthritis (RA), what is the diagnostic usefulness of anticyclic citrullinated protein antibodies (anti-CCP)? With a specificity of about 96% and a positive likelihood ratio of about 14, anti-CCP assists with the diagnosis of RA.

This paper is to examine the relationship between anti-cyclic citrullinated peptide (anti-CCP) antibody titers and the development of interstitial lung disease (ILD) in patients with and without rheumatoid arthritis (RA). A retrospective ...

Antibodies directed to cyclic citrullinated peptides (anti-CCP) are highly specific for rheumatoid arthritis (RA) and can easily be detected in sera by using commercially available immunoassays. The second version of the anti-CCP test (anti-CCP2) demonstrated high specificity (89-98%) and good sensitivity (41-88%) for RA.

2024年5月23日 · The development of anti‐CCP antibodies depends on various genetic factors, including shared epitope (SE), the alleles of HLA‐DRB1, and polymorphism in peptidyl arginine deiminase 4 (PADI4), as well as environmental factors such as smoking and infection with Porphyromonas gingivalis, the agent of periodontitis which may also affect the ...

Anti-cyclic citrullinated peptides (CCPs) are autoantibodies directed against citrullinated peptides. Rheumatoid factor (RF), an antibody against the Fc portion of IgG, is known to form immune complexes and contribute to the etiopathogenesis of various skin disorders.

We review the FDA regulatory updates for CCP collection during the pandemic and the challenges faced by blood donation centers, summarize the evidence for CCP efficacy, including efficacy against the SARS-CoV-2 variants and describe the future challenges and directions.

We investigated the risk of progression to RA overall and stratified by CCP antibody level (low: >1 to 2× the upper limit of normal [ULN]; medium: >2 to 3× ULN; high: >3× ULN). Multivariable Cox regression estimated the hazard ratio (HR) and 95% confidence interval (95% CI) …

This study compares the diagnostic performance of a second generation anti-cyclic citrullinated peptide antibody (CCP2) with a third generation anti-CCP antibodies assay (CCP3), as well as the combination of both tests.

The Association for the Advancement of Blood and Biotherapies (AABB) developed clinical practice guidelines for the appropriate use of CCP. Methods: These guidelines are based on 2 living systematic reviews of randomized controlled trials (RCTs) evaluating CCP from 1 January 2019 to 26 January 2022. There were 33 RCTs assessing 21 916 participants.

Anti-cyclic citrullinated peptide (anti-CCP) antibody testing is particularly useful in the diagnosis of rheumatoid arthritis, with high specificity, presence early in the disease process, and ability to identify patients who are likely to have severe disease and irreversible damage.